NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
August 20, 2020 14:11 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of...
Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
August 10, 2020 10:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain (available here) and provided an update on how Quell technology...
NeuroMetrix Reports Q2 2020 Financial Results
July 23, 2020 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading...
NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
July 16, 2020 15:14 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on...
NeuroMetrix Reports DPNCheck® Expansion in China
July 09, 2020 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test...
NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
June 25, 2020 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral...
NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
June 10, 2020 13:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes...
NeuroMetrix Reports Q1 2020 Financial Results
April 23, 2020 07:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020. The Company is a leading...
NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia
April 16, 2020 13:30 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmatic...
NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call
April 16, 2020 11:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on...